StreetAlpha.app
Home › Stocks › PEPG

PepGen Inc. (PEPG)

Healthcare
$3.78
▼ −3.82%
LAST CLOSE · NOV 20

PepGen develops treatments for severe neuromuscular diseases, starting with myotonic dystrophy type 1. It last closed at $3.78 on Nov 20, down 3.82% on the day. The next earnings report for PEPG is expected around Wed, Mar 3, 2027, after the close. For the quarter ended Sep 2026, PEPG reported EPS of -$0.28. Over its last 8 reports the stock moved an average of 31.5% the session after earnings. Over the last 12 months PEPG insiders bought $43.1M of stock on the open market and sold $59K, according to SEC Form 4 filings.

AI Auto Pilots
Is PEPG in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold PEPG.

Key Stats

Last 12 months
Results
Net income
−$73.3M
EPS (diluted)
−$0.77
Free cash flow
−$63.3M
Valuation
Market cap
$261.8M
69.3M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$22.0M
At Sep 30
Shareholder equity
$103.1M
Shares outstanding
69.3M
At Nov 4
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$27.3M−$27.3MFY2021FY2022: −$69.1M−$69.1MFY2022FY2023: −$78.6M−$78.6MFY2023FY2024: −$90.0M−$90.0MFY2024FY2025: −$89.7M−$89.7MFY2025

From PEPG's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 10). Last 12 months adds up the four latest quarters.

Next report
Mar 3
Estimated date · After the close
Reported EPS
-$0.28
Quarter ended Sep 2026
Year ago EPS
-$0.52
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.68Dec '24Mar 2025: -$0.92Mar '25Jun 2025: -$0.70Jun '25Sep 2025: -$0.52Sep '25Dec 2025: $0.02Dec '25Mar 2026: -$0.26Mar '26Jun 2026: -$0.26Jun '26Sep 2026: -$0.28Sep '26Latest -$0.28
Revenue by quarter
Not enough quarters on file yet.
How PEPG moved after its last 8 reports
Average move the session after a report ±31.5%
Nov 10, 2026Time not announced+92.9%
Aug 6, 2026Time not announced+21.7%
May 12, 2026After the close+6.0%
Mar 4, 2026After the close−18.6%
Nov 12, 2025Time not announced+10.3%
Aug 7, 2025Time not announced−13.1%
May 8, 2025Time not announced+22.2%
Feb 24, 2025Time not announced+67.2%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on PEPGStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on PEPG
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on PEPG

Technical Analysis

PEPG · as of the Nov 20 close · updated each morning
Uptrend

The stock is 13% above its 20 day and 24% above its 50 day average. It is 23% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 56). The nearest support is the Pivot S1 at $3.65, and the nearest resistance the Pivot at $3.81.

Short trendBullish
Long trendBullish
MomentumStrong
StretchNormal
VolatilityHigh, 13.7%/day
Key levels
$7.8052 week high+106.3%
$6.45Swing high (Nov 10)+70.6%
$3.95Pivot R1+4.5%
$3.81Pivot+0.8%
$3.78Last close
$3.65Pivot S1−3.4%
$3.62Swing low (Nov 17)−4.2%
$3.2920 day average−13.0%
$2.91200 day average−23.0%
$2.8850 day average−23.8%
$2.72100 day average−28.0%
$1.3152 week low−65.3%
Indicators
RSI (14)56.46Middle of its rangeNeutral
MACD0.39Above its signal lineBullish
Stochastic38.5Middle of its rangeNeutral
ADX (14)27.0Trending up
Williams %R-63.1Oversold below −80, overbought above −20Neutral
CCI (20)30.7Oversold below −100, overbought above 100Neutral
Rate of change+53.0%Change over 10 sessionsBullish
ATR (14)$0.52Typical daily range, 13.7% of price
MA 10Below
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for PEPG

What happened before

See how PEPG did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow PEPG usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How PEPG has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2022.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for PEPGHow many large options trades hit PEPG, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

PEPG Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲46 buying vs 30 selling
  • ▲Held by funds +3.3 pts
  • ▲Funds holding +12
  • ▼Superinvestors: 0 added, 4 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding8472+16.7%
In funds' top 1000–
Held by funds78.5%75.2%+3.3 pts
New / increased20 / 267 / 21+64.3%
Reduced / sold out22 / 825 / 27−42.3%
Put/call ratio0.00––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See PEPG institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

PEPG Insider Trading

All filings →
Insider trading · 12 months
Insiders are net buyers
Bought$43.1M1 buy · 1 insider
Sold$59K4 sales · 4 insiders
2026-03 sold $58K2026-05 sold $2K2026-11 bought $43.1MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 13Ra Capital Management, L.P.DirectorBuy8,625,000$5.00$43.1M
May 21Kasra KasraianChief Technical OfficerSale1,233$1.41$2K
Mar 4James G McArthurPresident and CEOSale5,275$6.23$33K
Mar 4Noel DonnellyCFOSale2,084$6.23$13K
Mar 4Paul StreckEVP, Head of R&DSale1,879$6.23$12K
Sep 30, 2025Oxford Science Enterprises plcInsiderBuy200,000$3.20$640K
Every insider buy and sale for PEPG over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See PEPG insider trades →

From SEC Form 4 filings by PEPG's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PEPG is in one of them and how their past PEPG trades turned out.

PEPG in the AI portfolios
Loading…

PEPG News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered PEPG in an article yet. Here's the latest on the wider market.

PEPG in the news

About PepGen

PepGen is a biotechnology company based in Boston, Massachusetts, that develops treatments for severe neuromuscular and neurologic diseases. Its lead candidate, PGN-EDODM1, is being developed for myotonic dystrophy type 1, a multi-system muscle disease with no approved therapies. The company's proprietary delivery platform uses peptides designed to carry short strands of genetic material into muscle and other cells, aiming to reach the cell nucleus. Its treatments remain in clinical trials and are intended for patients with these conditions.

Headquarters
Boston, MA